Platelet Patents (Class 424/93.72)
-
Patent number: 8802083Abstract: The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-?-1?4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving hemostasis.Type: GrantFiled: May 18, 2012Date of Patent: August 12, 2014Assignee: Marine Polymer Technologies, Inc.Inventors: John N. Vournakis, Sergio Finkielsztein
-
Publication number: 20140220085Abstract: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or both of them have charges with different electricity. The biomedical material is utilized for dentistry, orthopedics, wound healing or medical beauty and applied in the repair and regeneration of various soft and hard tissues.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: Industrial Technology Research InstituteInventors: Pei-Yi TSAI, Yi-Hung WEN, Zhi-Jie HUANG, Pei-Shan LI, Hsin-Hsin SHEN, Yi-Hung LIN, Chih-Hung CHEN
-
Patent number: 8796017Abstract: A blood storage container suitable for quick and efficient production of a large amount of serum while ensuring high safety, and a method of separating blood and a regenerative medical process using the same are provided. In a blood component separator 1 for separating collected blood into a plurality of blood components and preserving them, the separator 1 including a blood reservoir 10 for reserving the blood and a component storage part 20 aseptically connected in an air-tight manner to this blood reservoir 10, to the aforementioned blood reservoir 10 being imparted a serum producing function to remove coagulation factors from the blood to an extent enabling use in practical applications as a serum, and the aforementioned component storage part 20 storing each blood component generated by separation of the blood in the blood reservoir 10.Type: GrantFiled: May 21, 2004Date of Patent: August 5, 2014Assignee: JMS Co., Ltd.Inventors: Koji Suzuki, Junya Fujii, Mari Matsuura, Seishin Tanaka, Ken Kondo
-
Publication number: 20140212399Abstract: A hair growth agent having an effective dose of a platelet dry powder and a pharmaceutically acceptable solvent and/or excipient, wherein the effective dose refers to the presence of at least 1,000 platelets in every milliliter of the hair growth agent.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Central Medical Technologies Inc.Inventors: Chih I LIN, Han-Lei WAN
-
Publication number: 20140205582Abstract: Provided herein are methods of generating megakaryocyte lineage cells from hematopoietic stem cells in the absence of feeder cells and serum. The megakaryocyte progenitor cells (MKPs) generated as described result in rapid production of significant numbers of platelets when administered in vivo.Type: ApplicationFiled: July 6, 2012Publication date: July 24, 2014Applicant: CELLERANT THERAPEUTICS, INC.Inventors: Holger Karsunky, Chanawan Chanaukul, Swapna Pantuganti
-
Patent number: 8771672Abstract: The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and/or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20° C. and at shear rate of D=350 s?1, comprised between 100 and 250 c Poise and/or a Kinematic viscosity comprised between 99 and 248 cSt (measured at the same conditions); b) a culture of mesenchymal stem cells, and/or c) a platelet-rich hemo-derivative. This type of material in form of viscous liquid is particularly suitable for the therapy of osteoarthrosis, ligament damage, in particular tendon and cartilage damage) and may be administered intra-articularly, intradermally or directly applied in situ without altering the properties of the mesenchymal stem cells and/or platelets contained therein.Type: GrantFiled: June 29, 2010Date of Patent: July 8, 2014Assignee: Fidia Farmaceutici S.p.A.Inventors: Lanfranco Callegaro, Anna Maria Zanellato
-
Publication number: 20140186320Abstract: The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Inventor: Jae Woo Pak
-
Patent number: 8741282Abstract: Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. In particular, a method of treating a cardiac tissue lesion is disclosed.Type: GrantFiled: June 17, 2008Date of Patent: June 3, 2014Inventor: Allan Mishra
-
Publication number: 20140140987Abstract: A method of introducing healthy good human cells to eat up bad damaged cells, comprising administering an effective amount of a healthy good protein containing transferrin, alpha 1-antitrypsin, apolipoprotein A and human albumin. The method further comprises administering an effective amount of a protein containing ApoA1/2/4, or administering an effective amount of a protein containing Factor II, Factor VII, Factor IX and Factor X in prothrombin complex concentrate. The method can further comprise administering an effective amount of fibrinogen, Factor VIII, high concentrate fibrinogen, thrombin. hepatitis B immune globulin (HBIG), anti-thrombin III (AT-III), protein C, fibronectin, protein S and protein M.Type: ApplicationFiled: October 17, 2013Publication date: May 22, 2014Inventor: Kieu Hoang
-
Patent number: 8728466Abstract: This document provides methods and materials involved in treating burn injuries. For example, methods and materials for using skin grafts (e.g., autologous skin grafts) treated with an autologous platelet concentrate and autologous thrombin to treat burn injuries (e.g., deep skin burn injuries) are provided.Type: GrantFiled: November 22, 2011Date of Patent: May 20, 2014Assignee: University Hospital OstravaInventors: Vaclav Prochazka, Hana Klosova, Giannoula Lakka Klement
-
Publication number: 20140134211Abstract: Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations disclosed herein preferably include a blood component with a pharmaceutical agent. The blood component is preferably whole blood or platelet-rich plasma. The pharmaceutical agent may be a glucocorticoid hormone or other organic pharmaceutical agent. Particularly preferred pharmaceutical agents include dexamethasone, triamcinolone hexacetonide, melatonin, purmorphamine, 17?-estradiol, vitamin K2 (menaquinone-4, MK4,), bisphosphonates, derivatives thereof, and combinations thereof. The formulations may be directly administered to a surgical or injury site where improved bone growth is desired. The formulations may also be applied to or otherwise incorporated into scaffolding structural components commonly employed in the medical field to promote bone structure and growth. The pharmaceutical agent may be employed in an immediate release form or a sustained release form.Type: ApplicationFiled: April 8, 2011Publication date: May 15, 2014Inventor: James Louis RUTKOWSKI
-
Publication number: 20140121640Abstract: One aspect of the present disclosure relates to a method for forming a multipurpose membrane in vivo. One step of the method includes obtaining a blood component. Next, a vacuum assembly is operated to remove substantially all of the liquid from the blood component and thereby form a concentrated, substantially dehydrated blood component. The substantially dehydrated blood component is then formed into a non-coagulated injectable composition and administered to a wound of a subject.Type: ApplicationFiled: October 30, 2013Publication date: May 1, 2014Applicant: THE CLEVELAND CLINIC FOUNDATIONInventors: Peter J. Evans, Jim Trickett
-
Publication number: 20140105876Abstract: The invention relates to a ceramic biocomposite for bone regeneration, having a pH range of between 6.5 and 8.5, with an initial plasticity that allows the biocomposite to be easily moulded in situ and to set after 7 minutes, meaning that it can remain at the indicated location during the healing process. In addition, the biocomposite has demonstrated an ability to stimulate bone formation in hard-to-heal wounds. The material can act alone or in combination with other types of bone graft such as autografts, homografts or xenografts which act as a vehicle, as a binding material for endosseous prostheses or as a covering for endosseous implants or prostheses.Type: ApplicationFiled: March 27, 2012Publication date: April 17, 2014Applicant: UNIVERSIDAD AUTONOMA DE OCCIDENTEInventors: Sandra Arce Guerrero, Carlos Humberto Valencia
-
Patent number: 8697107Abstract: A flowable biomedical implant for application to a bone defect to promote bone growth is provided. The flowable biomedical implant comprises a carrier matrix including a biodegradable polysaccharide and ceramic material. An impermeable membrane can be integrally formed at the surface of the carrier matrix by applying a crosslinking agent to the biodegradable polysaccharide mixed with ceramic materials.Type: GrantFiled: April 27, 2012Date of Patent: April 15, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Susan J. Drapeau, Daniel A. Shimko
-
Publication number: 20140099293Abstract: A method of prevention/treatment of pathological consequences of DNA damage triggered by incorporation of circulating apoptotic chromatin fragments into healthy cells of individuals/patients in need therefore, said method comprising ex vivo or extra corporeal treatment of blood/plasma for removal of circulating chromatin fragments released from apoptotic cells which apoptotic chromatin fragments are capable of triggering DNA damage leading to genomic instability, senescence, apoptosis and cancerous transformation of healthy cells on being integrated into their genomesType: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Tata Memorial CentreInventors: Indraneel MITTRA, Urmila Chandrashekhar SAMANT, Gopesh Kumar MODI, Pradyumna Kumar MISHRA, Gobichettipalayam Subbaratnam BHUVANESHWAR
-
Publication number: 20140086891Abstract: Provided are compositions for promoting bone and cartilage growth. In certain embodiments, tissue graft compositions comprising a polymeric scaffold (e.g., PLGA), hyaluronic acid, and substantially purified mononucleated cells derived from bone marrow aspirate. In various embodiments, the tissue graft composition may comprise thrombin. The tissue grafts may be used to promote bone growth, e.g., in a spinal fusion operation.Type: ApplicationFiled: January 24, 2012Publication date: March 27, 2014Applicant: PROGENICARE, LLCInventors: Brooklyn Robertson, Jesse H. Sandstad
-
Publication number: 20140065120Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.Type: ApplicationFiled: June 21, 2013Publication date: March 6, 2014Inventors: Timothy C. Nichols, Thomas Fischer, Marjorie S. Read
-
Publication number: 20140065119Abstract: Compositions and methods for treating wounds are provided. The compositions include cyclic analogues of histatin (5).Type: ApplicationFiled: November 10, 2011Publication date: March 6, 2014Applicant: THE UNIVERSITY OF WESTERN ONTARIOInventors: Gilles Andre Lajoie, Greg John Adams Vilk, Ian Welch
-
Publication number: 20140065121Abstract: The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications.Type: ApplicationFiled: August 20, 2013Publication date: March 6, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Laura Suggs, Shanmugasundaram Natesan, Robert Christy, David Zamora
-
Patent number: 8663146Abstract: Methods for promoting angiogenesis comprising administering platelet-rich plasma to a site and stimulating the site with an electromagnetic field. Platelets include platelet-rich plasma and compositions can further include stem cells such as adipose stromal cells and cells derived from bone marrow aspirate. Methods also comprise isolating platelets from a patient's blood, forming a composition including the platelets, delivering the composition to a site in need of treatment, and electrically stimulating the site.Type: GrantFiled: September 16, 2011Date of Patent: March 4, 2014Assignee: Biomet Biologics, LLCInventors: Joel C. Higgins, Bruce Simon, Jennifer E. Woodell-May
-
Publication number: 20140056865Abstract: Embodiments of the present invention encompass compositions containing an adipose derived carrier, matrix, or filler, in some cases optionally in combination with bone particles or other granular materials or substances, for delivery to a human patient. Methods of manufacture and use of such adipose derived compositions are also disclosed.Type: ApplicationFiled: August 19, 2013Publication date: February 27, 2014Applicant: AlloSourceInventors: Adrian C. Samaniego, Derek J. Miller
-
Publication number: 20140050711Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.Type: ApplicationFiled: March 14, 2013Publication date: February 20, 2014Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Publication number: 20140050666Abstract: The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The invention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme.Type: ApplicationFiled: August 19, 2013Publication date: February 20, 2014Applicant: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: David H. Calhoun, Lane Gilchrist
-
Publication number: 20140010857Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction.Type: ApplicationFiled: September 9, 2013Publication date: January 9, 2014Inventor: ANTOINE TURZI
-
Patent number: 8617539Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of acute or chronic dysfunction of cardiac muscle. The method may employ a kit which includes a platelet-rich plasma composition and a pH adjusting agent and a catheter or syringe for delivery of the platelet-rich plasma composition to dysfunctional cardiac muscle. The kit may also include a syringe for withdrawing blood from a patient and a centrifuge device means to obtain platelet-rich plasma.Type: GrantFiled: March 13, 2012Date of Patent: December 31, 2013Inventor: Allan Mishra
-
Publication number: 20130344047Abstract: Methods and compositions for treating heart failure by administration of beneficial agents to the heart.Type: ApplicationFiled: August 30, 2013Publication date: December 26, 2013Applicant: ABBOTT CARDIOVASCULAR SYSTEMS, INC.Inventors: Stephen D. Pacetti, Jeffrey B. Huff, Paul Consigny
-
Publication number: 20130330311Abstract: Provided herein are methods of producing an antigen-presenting platelet. Also provided herein are methods of eliciting an immune response in a subject using the antigen-presenting platelets described herein. Also provided are methods of screening for an immune response elicited by an antigen-presenting platelet. Further provided are isolated populations of platelets that present a selected antigen produced by the methods described herein.Type: ApplicationFiled: February 22, 2012Publication date: December 12, 2013Applicant: UNIVERSITY OF ROCHESTERInventor: Craig Morrell
-
Patent number: 8595950Abstract: Described herein are devices and techniques for spray drying a fluid to produce a dried powder. Assemblies include a spray drying head attachable to a gas supplier and a liquid sample, such as a standard unit of blood product. The spray drying head can be adapted to provide an aerosolized flow of liquid sample exposed to a drying gas. The assembly also includes a drying chamber adapted to separate the aerosolized flow of liquid sample into a dried powder and humid air. The assembly can be disposable, provided in a sterilized kit and having simplified attachments allowing quick connect and disconnect from the gas and liquid sample. Separation of the powder from the humid air exiting the drying chamber occurs within a filtered collection bag. In some embodiments, one or more of the drying chamber and collection bag are formed form a thin-walled, collapsible material.Type: GrantFiled: May 17, 2012Date of Patent: December 3, 2013Assignee: Velico Medical, Inc.Inventors: Dennis Brian Hubbard, Jr., Michael Haley, John Charles Rosenfelder, George T. Perivolotis
-
Publication number: 20130309214Abstract: A method of producing an injectable calcium phosphate paste by a process in which calcium phosphate precursors are mixed with the setting fluids to form a self-hardened apatite cement is disclosed. The produced apatite cement is biocompatible, bioactive and biodegradable in the body. The pH value of said apatite cement is approximately 7 with compressive strength between 10-30 MPa and the setting process will not generate.temperature >37° C. The self-hardened apatite (SHA) cement is found to be bioresorbable and can be used for bone fillers, fixation of broken bones or artificial joints in human and also appropriate for use as a delivery vehicle.Type: ApplicationFiled: September 29, 2011Publication date: November 21, 2013Applicant: SIRIM BERHADInventors: Fazilah Binti Fazan, Salina Sabudin, Shirin Binti Ibrahim, Sudirman Bin Sahid, Wan Ruzaini Bin Wan Sulaiman, Nor Shahida Binti Kader Bashah
-
Publication number: 20130287753Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.Type: ApplicationFiled: June 28, 2013Publication date: October 31, 2013Inventor: Christopher J. Centeno
-
Patent number: 8529959Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529958Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529961Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carmell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529960Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: July 6, 2011Date of Patent: September 10, 2013Assignees: Carnell Therapeutics Corporation, Allegheny-Singer Research Institute, Carnegie Mellon UniversityInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8529956Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: GrantFiled: April 17, 2008Date of Patent: September 10, 2013Assignees: Carnell Therapeutics Corporation, Carnegie Mellon University, Allegheny-Singer Research InstituteInventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8517967Abstract: The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.Type: GrantFiled: November 8, 2011Date of Patent: August 27, 2013Assignee: Velico Medical, Inc.Inventors: Keith Rosiello, Henrik Clausen
-
Patent number: 8518398Abstract: A method for treating an open wound, such as a surgical wound, may include preparing a first composition including a platelet poor plasma (PPP), and preparing a second composition including a platelet rich plasma (PRP). A layer of the first composition may be applied within the open wound, and a layer of the second composition may be applied within the open wound over the layer of the first composition.Type: GrantFiled: April 13, 2010Date of Patent: August 27, 2013Inventor: Richard A. Hynes
-
Patent number: 8512697Abstract: The invention is directed to platelets containing micron or nanometer size particles wherein the micron or nanometer sized particles comprises an active agent. The invention is also directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the above platelets. The invention is further directed to methods of delivering the micron or nanometer size particles containing an active agent to a site of interest in a patient.Type: GrantFiled: April 29, 2008Date of Patent: August 20, 2013Assignee: The University of North Carolina at Chapel HillInventors: Thomas H. Fischer, E. Stan Eskridge, Jr., Timothy C. Nichols, Caterina Maria Gallippi
-
Patent number: 8501170Abstract: The present invention relates to platelet fractions which can be obtained from placental blood, with high concentrations of platelet factors as well as gels and lysates deriving therefrom. The invention further relates to methods for preparing said platelet fractions from placental blood, and to the uses thereof as such or as platelet gels or as lysates.Type: GrantFiled: July 14, 2009Date of Patent: August 6, 2013Assignee: Fondazione IRCCS “CA' Granda—Ospedale Maggiore Policlinico”Inventors: Paolo Rebulla, Lorenza Lazzari, Valentina Parazzi, Noemi Greppi
-
Publication number: 20130197468Abstract: Methods and apparatuses for delivery of biologically active material and/or sensors to a target organ or system. The apparatuses allow for specific, controlled delivery of the biologically active material and targeted placement of sensors. The apparatuses may be fabricated from cellular and/or acellular biological active components to promote integration of sensors into tissue and achieve appropriate release of biologically active molecules. The apparatuses may be fabricated from plasma-containing materials or other biopolymers such that the apparatus will resorbed into the tissue following insertion. The biologically active cellular or acellular component may be incorporated into that material may then serve as the source of the therapeutic biologically active component. The apparatus may take the form of a screw, though numerous shapes arc contemplated.Type: ApplicationFiled: January 28, 2013Publication date: August 1, 2013Applicants: CARNEGIE MELLON UNIVERSITY, University of Pittsburgh-of the Commonwealth System of Higher EducationInventors: David SCHWARTZMAN, Lee E. Weiss, Phil Gordon Campbell, Gary K. Fedder
-
Patent number: 8492081Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.Type: GrantFiled: September 28, 2007Date of Patent: July 23, 2013Assignee: The University of North Carolina at Chapel HillInventors: Timothy C. Nichols, Thomas Fischer, Marjorie S. Read
-
Patent number: 8486617Abstract: The present invention provides processes for preparing freeze-dried platelets, freeze-dried platelets made by those processes, platelets reconstituted from those freeze-dried platelets, methods of using the platelets for therapeutic, diagnostic, and research purposes, and kits comprising the freeze-dried platelets.Type: GrantFiled: August 12, 2005Date of Patent: July 16, 2013Assignee: Cellphirc, IncInventors: David Ho, Cindy S. Orser, Alan S. Rudolph, Keith Moskowitz, Joshua Dee
-
Publication number: 20130177541Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: ApplicationFiled: November 3, 2011Publication date: July 11, 2013Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
-
Publication number: 20130172668Abstract: A method of manufacturing a composition for enlarging the penis comprises the steps of picking the auto-tissue of a skin from the abdomen or flank region of a patient; (2) obtaining a purified mixture of the dermis and fat by removing the red blood cells of a lower layer from the auto-tissue through centrifugation; (3) separating and extracting stem cells from part of the purified mixture; (4) picking blood from the patient and purifying the blood through centrifugation; (5) extracting a Platelet Rich Plasma (PRP), including rich growth factors, from the purified blood; and (6) fabricating the composition by mixing the mixture obtained at the step (2) and not used to extract the stem cells, the stem cells, and the Platelet Rich Plasma (PRP).Type: ApplicationFiled: January 4, 2012Publication date: July 4, 2013Inventor: Jae-Young KIM
-
Publication number: 20130131639Abstract: Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.Type: ApplicationFiled: November 2, 2012Publication date: May 23, 2013Inventor: Sherrill J. Slichter
-
Patent number: 8444969Abstract: Compositions and methods for preparing neutrophil-depleted platelet rich plasma are provided. Generally, these compositions comprise a higher concentration of platelets and depressed concentrations of neutrophils relative to whole blood although white blood cells may be at higher concentrations than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The neutrophil-depleted platelet rich plasma composition may be delivered in conjunction with reperfusion therapy.Type: GrantFiled: December 21, 2011Date of Patent: May 21, 2013Inventor: Allan Mishra
-
Publication number: 20130121979Abstract: Platelets are concentrated from the blood of a patient. The platelets are unactivated or are treated by a method such as ultrasound or agitation to obtain platelet releasate. The platelets are formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer.Type: ApplicationFiled: September 28, 2012Publication date: May 16, 2013Inventor: Allan Mishra
-
Patent number: 8440459Abstract: Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets and white blood cells than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.Type: GrantFiled: October 8, 2009Date of Patent: May 14, 2013Inventor: Allan Kumar Mishra
-
Publication number: 20130101637Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.Type: ApplicationFiled: October 16, 2012Publication date: April 25, 2013Applicant: SEARETE LLCInventor: SEARETE LLC
-
Publication number: 20130095087Abstract: An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed.Type: ApplicationFiled: October 17, 2011Publication date: April 18, 2013Applicant: POLY-MED, INC.Inventors: Shalaby W. Shalaby, Joel Corbett, Jason Olbrich